Skip to main content
Fig. 5 | Virology Journal

Fig. 5

From: Interleukin-17A pretreatment attenuates the anti-hepatitis B virus efficacy of interferon-alpha by reducing activation of the interferon-stimulated gene factor 3 transcriptional complex in hepatitis B virus-expressing HepG2 cells

Fig. 5

Effect of IL-17A pretreatment on the expression of anti-HBV or regulatory IFN-stimulated genes (ISGs). HepG2-HBV1.3 cells were pretreated with or without 50 ng/ml IL-17A for 24 h, followed by co-treatment with or without 1000 IU/ml IFN-α for 24 or 48 h. Total cellular RNA were extracted for detection of mRNA expression of anti-HBV ISGs (ISG15, ISG20, MxA and OAS) (A) and regulatory ISGs (SOCS1, SOCS3 and USP18) (B) by RT-qPCR. Relative expression of mRNA was shown as fold-change compared to the mock-treated cells. Data were shown as mean ± standard deviation (SD) (error bars) from at least 3 independent experiments. p < 0.05 is considered statistically significant. *p < 0.05, **p < 0.01 between two indicated groups

Back to article page

Virology Journal

ISSN: 1743-422X